每经记者｜章光日 每经编辑｜吴永久 博雅生物持续聚焦血液制品核心主业，作为国内领先的血液制品生产企业之一，产品涵盖白蛋白、人免疫球蛋白和凝血 因子三大类10个品种（不含进口重组Ⅷ因子）31个规格。截至2025年6月30日，公司共拥有21家单采血浆站，其中在营 浆站20个。 博雅生物于2012年上市，上市之后，公司始终保持了不错的净利润表现。不过，2025年博雅生物的业绩表现不佳，迎来 上市后首个扣非净利润预亏。 近期，博雅生物总裁任辉辞职，而其任职时间不足10个月。博雅生物2012年上市，上市后净利润表现一直不错。不过， 2025年度公司扣非净利润预计出现亏损。博雅生物的扣非净利亏损主要由于并购公司资产减值所致。《每日经济新闻》 记者（以下简称每经记者）发现，上述并购项目在任辉担任博雅生物副总裁后不久完成。 2月27日早间，博雅生物发布了关于公司董事暨总裁辞任的公告。该公告显示，因工作变动原因，公司董事、总裁任辉 申请辞去公司第八届董事会董事、战略与ESG委员会委员及总裁、法定代表人的职务，辞任后将不再担任公司任何职 务。任辉离任后，博雅生物总裁职务将暂时处于空缺状态，而公司董事会将按照有关规定，尽快推进董事 ...

Core Viewpoint - The company, Hualan Vaccine, emphasizes its strong collaboration with its controlling shareholder, Hualan Biological, in various aspects such as biopharmaceutical research and development, production quality system construction, supply chain management, and compliance experience [1] Group 1 - The company and Hualan Biological are committed to building and managing the "Hualan" brand, which has been recognized as a well-known trademark in China, indicating good market recognition and brand reputation [1] - Some vaccine products from the company have complementary clinical applications with related immunological products from Hualan Biological, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to achieve synergistic effects of active and passive immunity [1]

Core Viewpoint - The company, Hualan Vaccine, emphasizes its collaborative development with its controlling shareholder, Hualan Biological, focusing on shared resources and complementary product offerings in the vaccine sector [1] Group 1: Collaboration and Synergy - The company and Hualan Biological have established a solid foundation for collaboration in areas such as bioproduct research and development management, production quality system construction, supply chain management, and compliance experience [1] - Both entities are committed to the construction and management of the "Hualan" brand, which has been recognized as a famous trademark in China, indicating strong market recognition and brand reputation [1] Group 2: Product Complementarity - Certain vaccine products from the company have complementary applications with Hualan Biological's related immunological products, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to enhance both active and passive immunity [1]

Core Viewpoint - Shanghai Laishi (002252) has confirmed that several of its products have been included in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List [2] Group 1: Product Inclusion in Medical Insurance - The following products from Shanghai Laishi and its subsidiaries are included in the medical insurance directory: human albumin, intravenous human immunoglobulin (PH4), human fibrinogen, prothrombin complex, coagulation factor VIII, human immunoglobulin, tetanus human immunoglobulin, and rabies human immunoglobulin [2]

Core Viewpoint - The control of the domestic blood product company, Palin Bio (000403), is set to change hands as its controlling shareholder, Shengbang Yinghao Investment Partnership, has signed a share transfer agreement with China National Biotechnology Group, which will acquire 21.03% of the shares for approximately 4.699 billion yuan, making it the new controlling shareholder of the company [1][2]. Group 1: Share Transfer Details - Shengbang Yinghao will transfer a total of 199,878,656 shares, representing 21.03% of the total share capital, to China National Biotechnology Group at a price of approximately 46.99 billion yuan, equating to about 23.51 yuan per share, which reflects a premium of approximately 27.77% over the closing price of 18.4 yuan per share on September 9 [2][8]. - Following the completion of the share transfer, the controlling shareholder will shift from Shengbang Yinghao to China National Biotechnology Group, with the actual controller changing from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to China National Pharmaceutical Group [2][4]. Group 2: Company Performance and Industry Context - Palin Bio's main business involves the research, development, production, and sales of blood products, which are derived from human plasma and include human albumin, human immunoglobulin, and human coagulation factors [6][10]. - In the first half of 2025, Palin Bio reported a revenue of 986 million yuan, a year-on-year decrease of 13.18%, and a net profit attributable to shareholders of 236 million yuan, down 27.89% [8][9]. - The decline in performance is attributed to the growing pains of expansion, as the company has been increasing its plasma collection capacity, which has temporarily reduced product supply [9][10]. Group 3: Industry Dynamics and Competition - Since 2001, China has stopped approving new blood product manufacturing enterprises, leading to a competitive landscape dominated by major players such as Tian Tan Bio, Shanghai Lai Shi, Hualan Bio, and Palin Bio [1][10]. - The acquisition of Palin Bio by China National Biotechnology Group signifies a further increase in industry concentration, as the group already controls Tian Tan Bio, the largest blood product company in China [11][12]. - Post-acquisition, there will be potential competition issues as both Palin Bio and Tian Tan Bio produce overlapping blood product categories, which may lead to market competition concerns [12].

Core Viewpoint - The control of the blood product company, Pailin Biological, is set to change hands to China National Pharmaceutical Group (Sinopharm) through a share transfer agreement valued at approximately 4.699 billion yuan, marking a significant consolidation in the blood products industry in China [2][3][11]. Company Summary - Pailin Biological's major business involves the research, development, production, and sales of blood products, which are derived from healthy human plasma using biological processes [8]. - The company currently has three main product categories: human albumin, human immunoglobulin, and human coagulation factors, totaling 11 product varieties [8]. - Despite a decline in revenue and net profit in the first half of 2025 due to expansion pains, Pailin Biological's plasma collection volume exceeded 770 tons, reflecting an 11% year-on-year increase [9]. Industry Summary - Since 2001, China has halted the approval of new blood product manufacturing enterprises, leading to a controlled total output and a competitive landscape dominated by major players like Tian Tan Biological, Shanghai Lai Si, Hualan Biological, and Pailin Biological [10]. - The acquisition of Pailin Biological by Sinopharm signifies a rapid increase in market concentration, as Sinopharm already owns Tian Tan Biological, the largest blood product company in China [11]. - The combined plasma collection capacity of Tian Tan Biological and Pailin Biological is projected to exceed 4,000 tons in 2024, accounting for nearly 30% of the total plasma collection in the industry [12].

Investment Rating - The report maintains a "Buy" rating for the company [6][13] Core Views - The company is steadily increasing its plasma collection volume and expanding the number of plasma stations through both organic growth and acquisitions. The introduction of new products, particularly the 10% immunoglobulin, is expected to contribute to revenue growth [2][13] - The financial forecast indicates a projected revenue increase from 1,943 million yuan in 2025 to 2,466 million yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 12% [4][14] - The net profit attributable to shareholders is expected to rise from 461 million yuan in 2025 to 666 million yuan in 2027, with a corresponding increase in earnings per share (EPS) from 0.91 yuan to 1.32 yuan [4][14] Financial Summary - Total revenue for 2023 is reported at 2,652 million yuan, with a forecasted decline to 1,735 million yuan in 2024, followed by a recovery to 1,943 million yuan in 2025 [4] - The net profit attributable to shareholders is projected to decrease from 237 million yuan in 2023 to 397 million yuan in 2024, before increasing to 461 million yuan in 2025 [4] - The company’s return on equity (ROE) is expected to improve from 3.2% in 2023 to 7.5% by 2027 [4][14] Market Data - The current stock price is 25.77 yuan, with a target price set at 30.18 yuan, indicating a potential upside [6][7] - The company has a market capitalization of approximately 12,994 million yuan and a price-to-earnings (P/E) ratio of 54.72 for 2023, which is expected to decrease to 19.51 by 2027 [4][7] Industry Context - The company operates within the pharmaceutical and essential consumer goods sector, focusing on blood products [5]

Group 1 - The core business of the company is the research, production, and sales of blood products, not involving vaccine business [1] - The company operates in the blood products industry [1] - The company has three main categories of products on the market: human albumin, human immunoglobulin, and human coagulation factors, along with recombinant coagulation factor products [1]

Group 1 - The company does not engage in vaccine development, specifically for HIV vaccines [2] - The main business of the company is the research, production, and sales of blood products [2] - The company operates in the blood products industry, with key products including human albumin, human immunoglobulin, and human coagulation factors, as well as recombinant coagulation factor products [2]

Core Viewpoint - The company, Weiguang Biological, plans to significantly expand its production capacity in the blood products sector, aiming to increase its output to 1,200 tons, which is 1.85 times its current capacity, through a fundraising initiative of up to 1.5 billion yuan [1][4][6]. Group 1: Company Expansion Plans - Weiguang Biological's fundraising plan includes raising no more than 1.5 billion yuan, with 1.2 billion yuan allocated for the construction of an intelligent industrial base and 300 million yuan for working capital [1][4]. - The total investment for the intelligent industrial base project is estimated at 2.308 billion yuan, with a construction period of 4.5 years [5][6]. - The company aims to produce various blood products, including human albumin and immunoglobulin, with the new facility expected to enhance its product offerings [6][17]. Group 2: Industry Context - The blood products industry is experiencing a wave of expansion, with several leading companies already establishing or constructing large-scale production bases [3][16]. - The demand for blood products is anticipated to grow due to an aging population and improved healthcare conditions, with the market projected to reach approximately 60 billion yuan in 2024 and 95 billion yuan by 2030 [9][10]. - The industry is characterized by a supply-demand imbalance, with domestic consumption of blood products still lagging behind international levels [8][10]. Group 3: Financial Challenges - The company faces a funding gap of 1.108 billion yuan even after the planned fundraising, as its current cash reserves are insufficient to meet investment needs [27][29]. - Weiguang Biological's asset-liability ratio stands at 30.47%, significantly higher than the industry average, which raises concerns about its financial stability [30][32]. - The company has experienced a slight decline in revenue and net profit in the first quarter of 2025, indicating potential financial pressures amid its expansion efforts [32].